Skip to main content
SP5007,783.63-0.20%DOW53,767.18-0.14%NASDAQ26,695.72-0.40%BTC$62,996.00-0.24%ETH$1,876.20-0.06%GOLD$4,438.60+0.41%OIL$82.15+1.11%
Smart Investors Daily
Sign InSign Up Free
VA

NASDAQ · VACC

Vaccitech plc

Healthcare · Biotechnology

$5.00

Up+$0.51 (+11.36%)

Updated Aug 14, 2026, 6:19 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
192.73M
P/E ratio
-0.39
Dividend yield
0.00%
52-week range
— – —
Volume
163.05K
Avg. volume
719.04K

Price performance

VACC price history

1M range · 0 trading sessions · Daily adjusted prices

VACC does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest VACC news

The latest Smart Investors Daily articles mentioning VACC.

Stock researchCompany · Overview

VACC research

Overview

Company profile and research snapshot.

Company profile

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
VACC recent ratings
DateFirmRatingTarget
Sep 25, 2023Alliance Global PartnersBuy—
Sep 25, 2023Morgan StanleyEqual-Weight—
Aug 18, 2023Morgan StanleyOverweight—
Jun 13, 2023HC Wainwright & Co.Buy—
May 16, 2023Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Nov 6, 2023

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, November 10-14 in Boston, MA.

PennyStocks · Sep 26, 2023

How to Get Started Trading Penny Stocks: Quick Guide

Here's 3 tips to get started trading penny stocks The post How to Get Started Trading Penny Stocks: Quick Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GlobeNewswire Inc. · Sep 13, 2023

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and potential paths to a functional cure. Details are as follows:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By